Trial document

This trial has been registered retrospectively.
drksid header


Trial Description

start of 1:1-Block title


Prospective comparison of FDG-PET and IBZM-SPECT in the differential diagnosis of parkinsonism

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The major objective of our study is to improve the diagnostic accuracy of uncertain parkinsonism. In particular at early stages of disease the clinical diagnosis is challenging. Neuroimaging techniques contribute to the correct diagnosis of parkinsonism. Potential study participants are patients who suffer from symptoms of parkinsonism. Our study aims for a a head-to-head comparison of two radioactive imaging methods (FDG-PET and IBZM-SPECT). FDG-PET is radioactive imaging of glucose metabolism of nerve cells. IBZM-SPECT is radioactive imaging of dopamine receptor in the brain. Dopamin is a transmitter which is decreased in the brain of parkinsonian patients.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Imaging of regional cerebral glucose metabolism with positron emission tomography (PET) and striatal dopamine D2/D3 receptors (D2R) with single-photon emission computed tomography (SPECT) improves the differential diagnosis of parkinsonism. We prospectively investigated (1.) the diagnostic merits of these approaches in differentiating between Lewy body diseases (LBD; majority Parkinson’s disease, PD) and atypical parkinsonian syndromes (APS); (2.) the diagnostic value of [18F]FDG-PET to differentiate among APS subgroups.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003613
  •   2012/03/12
  •   [---]*
  •   yes
  •   Approved
  •   361/08, Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   G20 -  Parkinson's disease
  •   G23.1 -  Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]
  •   G31.0 -  Circumscribed brain atrophy
  •   G90.3 -  Multi-system degeneration
  •   G31.88 -  [generalization G31.8: Other specified degenerative diseases of nervous system]
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Patients with clinically suspected atypical parkinsonian syndromes (based on clinical symptoms and poor response to levodopa) receive IBZM-SPECT. All patients were clinically followed up for at least 6 months for final clinical diagnosis.
  •   Patients with clinically suspected atypical parkinsonian syndromes (based on clinical symptoms and poor response to levodopa) receive FDG-PET. All patients were clinically followed up for at least 6 months for final clinical diagnosis.
    The same study sample receives first IBZM-SPECT (Arm1) and subsequently FDG-PET.
end of 1:N-Block interventions
start of 1:1-Block design


  •   Non-interventional
  •   Other
  •   Non-randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control
  •   Diagnostic
  •   Other
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

diagnostic accuracy of IBZM-SPECT and FDG-PET to differentiate between atypical parkinsonian syndromes and Lewy body diseases (Parkinson´s disease, Parkinson´s disease with dementia, Dementia with Lewy bodies) given as area under the receiver operating characteristics

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

diagnostic accuracy of FDG-PET to differentiate between subgroups of atypical parkinsonian disorders (progressive supanuclear palsy, corticobasal degeneration, multiple system atrophy), diagnostic measures are sensitivity, specificity, negative predictive value, positive predictive value

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Actual
  •   2010/07/05
  •   100
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

suspected, but not yet verified early-stage atypical parkinsonian syndrome based on clinical symptoms and poor response to levodopa; Karnofsky score ≥40%)

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

relevant impairment or significant reduction of life expectancy caused by another disease

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Abteilung für Nuklearmedizin, Universitätsklinikum Freiburg
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up complete
  •   2011/06/27
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.